{"product_id":"ocul-marketing-mix","title":"(OCUL) Ocular Therapeutix, Inc. Marketing Mix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Ocular Therapeutix, Inc. 4P's Marketing Mix Analysis summarizes the company’s products (ophthalmic drug-delivery and therapies), their clinical uses, pricing approaches, distribution channels, and promotional tactics. This page shows a real preview\/sample of the analysis so you can review style and content; purchase the full version to receive the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReSure Sealant\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReSure Sealant is a bioresorbable hydrogel ophthalmic device made to stop fluid leakage from corneal incisions after cataract surgery. It supports wound closure in the operating room and was built for the millions of cataract procedures done each year, with more than 20 million performed worldwide. For Ocular Therapeutix, Inc., it fits the product mix as a surgeon-used, procedure-linked device with clear clinical value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDEXTENZA 0.4 mg\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDEXTENZA 0.4 mg is Ocular Therapeutix, Inc.'s dexamethasone intracanalicular insert for the Product part of the 4P mix. It is FDA approved for post-surgical ocular inflammation and pain, plus allergic conjunctivitis, and it releases steroid for about 30 days. That long, once-administered delivery supports surgeon use and helps reduce repeat dosing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOTX-TKI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOTX-TKI is Ocular Therapeutix’s axitinib intravitreal implant, now in Phase 1, aimed at wet age-related macular degeneration and other retinal diseases. Its value is tied to a large retina market, as wet AMD is a leading cause of severe vision loss in older adults. Early data will matter most, because this product could support longer-acting treatment with fewer injections.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOTX-TIC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOTX-TIC is Ocular Therapeutix, Inc.’s travoprost intracameral implant, now in Phase 2 for open-angle glaucoma and ocular hypertension. In the 4P mix, it fits a premium, procedure-based product aimed at lowering pressure with less frequent dosing than daily eye drops. The Phase 2 stage means clinical proof is still being built before any 2026 commercialization path.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 2 asset for 2 eye-disease indications\u003c\/li\u003e\n\u003cli\u003eTravoprost delivery via intracameral implant\u003c\/li\u003e\n\u003cli\u003eBuilt for longer-acting pressure control\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOTX-CSI and OTX-DED\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOTX-CSI is a cyclosporine intracanalicular insert that has completed Phase 2 for dry eye disease, while OTX-DED is a dexamethasone insert in Phase 2 for short-term dry eye symptom relief.\u003c\/p\u003e\n\u003cp\u003eBoth products extend Ocular Therapeutix, Inc. sustained-release hydrogel platform into chronic eye care, aiming to improve dosing convenience and adherence versus daily eye drops.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase 2 assets in dry eye care\u003c\/li\u003e\n\u003cli\u003eSustained-release hydrogel delivery\u003c\/li\u003e\n\u003cli\u003eTargets chronic symptom management\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOcular Therapeutix Builds on DEXTENZA as Pipeline Expands\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOcular Therapeutix, Inc.’s Product mix centers on procedure-linked, sustained-release eye care: ReSure Sealant for cataract incision closure, DEXTENZA 0.4 mg for 30-day post-op inflammation and pain, and pipeline assets for retina, glaucoma, and dry eye. In 2025, DEXTENZA remained the key marketed drug, while the pipeline kept the platform tied to large, recurring ophthalmology volumes.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDEXTENZA\u003c\/td\u003e\n\u003ctd\u003eFDA approved\u003c\/td\u003e\n\u003ctd\u003e30-day steroid insert\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTX-TKI\u003c\/td\u003e\n\u003ctd\u003ePhase 1\u003c\/td\u003e\n\u003ctd\u003eWet AMD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, company-specific breakdown of Ocular Therapeutix, Inc.’s Product, Price, Place, and Promotion strategy, grounded in real market positioning and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCondenses Ocular Therapeutix’s 4Ps into a quick, decision-ready view that eases analysis and speeds team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise bibliography linking Ocular Therapeutix claims to industry reports, FDA filings, clinical trials, and market datasets for swift, defensible due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePlace\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. ophthalmology specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOcular Therapeutix focuses on U.S. ophthalmologists and cataract surgeons in specialty clinics and surgery centers. The U.S. has about 20,000 practicing ophthalmologists, and cataract surgery tops 3.7 million cases a year, giving the brand a large repeat-use base. Its inserts and sealants fit high-volume procedural settings where surgeons value fast placement and predictable recovery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmbulatory surgery centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmbulatory surgery centers are a core channel for Ocular Therapeutix, Inc. because DEXTENZA and ReSure Sealant fit same-day cataract workflows and can be used at the point of care. ASCs handle most U.S. cataract surgery volume, with the CMS 2025 ASC payment list including hundreds of covered procedures, so access here matters. These sites favor products that save time, reduce extra handling, and support fast discharge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOffice-based eye clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOffice-based eye clinics are the key channel for Ocular Therapeutix, Inc. because DEXTENZA is placed by eye-care professionals during in-clinic visits, not sold through consumer retail. This matters most for allergic conjunctivitis and post-surgical care, where office use supports same-day treatment and repeat patient flow. The model fits a specialty product with no need for broad pharmacy shelf space.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-led international markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOcular Therapeutix uses partner-led markets to extend DEXTENZA and OTX-TIC beyond its U.S. field force, which keeps selling costs lighter while it builds reach. AffaMed Therapeutics handles commercialization in Greater China, and Regeneron supports retinal disease development, including aflibercept-related work. This model matters because Ocular reported $59.5 million in 2024 revenue, up 49% year over year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAffaMed expands non-U.S. access.\u003c\/li\u003e\n\u003cli\u003eRegeneron backs retinal R\u0026amp;D.\u003c\/li\u003e\n\u003cli\u003ePartners reduce direct-sales burden.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBedford, Massachusetts headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOcular Therapeutix, Inc. is headquartered in Bedford, Massachusetts, and that site anchors its corporate, clinical, and commercial work. The Bedford base supports its ophthalmic development platform and keeps R\u0026amp;D and go-to-market teams close to Boston’s biotech talent pool.\u003c\/p\u003e\n\u003cp\u003eAs of fiscal 2025, this location remained the company’s main operating hub for pipeline work and business execution. It helps align development, regulatory, and commercial planning in one place, which matters for a specialty eye-care company with a focused U.S. footprint.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBedford is the corporate hub.\u003c\/li\u003e\n\u003cli\u003eSupports clinical and commercial teams.\u003c\/li\u003e\n\u003cli\u003eCenters ophthalmic platform work.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOcular Therapeutix: U.S. Ophthalmology Reach, Bedford HQ, China Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOcular Therapeutix, Inc. places its products through U.S. ophthalmology offices and ambulatory surgery centers, where same-day cataract and post-op care drive use. Bedford, Massachusetts is the fiscal 2025 operating hub for clinical and commercial execution. Partner channels in Greater China extend reach beyond the U.S. footprint.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePlace\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. core\u003c\/td\u003e\n\u003ctd\u003e~20,000 ophthalmologists; 3.7M+ cataract cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeadquarters\u003c\/td\u003e\n\u003ctd\u003eBedford, MA; fiscal 2025 hub\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eOcular Therapeutix, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual document you’ll receive instantly after purchase—no surprises. This Ocular Therapeutix 4P's Marketing Mix analysis is complete, editable, and ready to use, covering Product, Price, Place, and Promotion with actionable insights and industry context. Buy with confidence—what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePromotion\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty sales force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOcular Therapeutix, Inc. uses a specialty sales force to reach 3 core physician groups: ophthalmologists, cataract surgeons, and retina specialists. This field model fits physician-administered products like DEXTENZA, so promotion is built around clinic access, procedure use, and repeat prescribing, not broad consumer ads. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical data publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOcular Therapeutix, Inc. promotes through trial results and peer-reviewed publications, using Phase 1 and Phase 2 data to support each product story. That matters in eye care, where physicians lean on clinical outcomes, safety, and durability before adopting a treatment. Strong published evidence helps turn pipeline data into trust and demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical congress presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOcular Therapeutix uses medical congress presence to reach surgeons, investigators, and key opinion leaders at ophthalmology meetings, where it can build awareness for both commercial products and pipeline assets. In 2025, the company kept AXPAXLI and DEXTENZA in front of clinicians at major scientific forums, which matters because U.S. ophthalmic procedure volumes top 4 million cataract surgeries a year. That direct access can speed adoption and trial interest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eReimbursement support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eReimbursement support is a key promotion lever for Ocular Therapeutix, Inc., because it helps clinics manage coverage, billing, and site-of-care economics. For buy-and-bill specialty products and devices, that matters: Medicare Part B usually leaves patients with 20% coinsurance, so access help can reduce delays and denials.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003ePayer education lowers claim friction.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBilling support helps clinic cash flow.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSite-of-care guidance can protect margins.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eAccess help is vital in buy-and-bill.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership and investor communications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOcular Therapeutix, Inc. uses partnership news to back up its pipeline story, and the named ties to Regeneron, AffaMed, and Mosaic Biosciences give the platform outside validation. Investor updates help explain where development stands and why the science matters. One clear message: third-party links can make early-stage assets look less speculative.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003e3 named collaborations broaden reach\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eInvestor updates explain platform progress\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eExternal names support pipeline credibility\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocused Eye-Care Promotion Drives Trust, Access, and Prescribing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOcular Therapeutix, Inc. promotes DEXTENZA and AXPAXLI through a specialty sales force, not mass consumer ads, so the message stays focused on ophthalmologists, cataract surgeons, and retina specialists. It backs this with peer-reviewed data, congress presence, and reimbursement support to cut access friction and speed prescribing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePromotion lever\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eField sales\u003c\/td\u003e\n\u003ctd\u003eTargets 3 physician groups\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical evidence\u003c\/td\u003e\n\u003ctd\u003eBuilds trust in therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess support\u003c\/td\u003e\n\u003ctd\u003eLowers billing and pay issues\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePrice\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-use per procedure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOcular Therapeutix, Inc. uses a single-use, procedure-linked price model: DEXTENZA is a 0.4 mg insert used once per eye treatment episode, and ReSure Sealant is a one-time surgical product.\u003c\/p\u003e\n\u003cp\u003eThat pricing fits short, in-office use and supports repeat demand by procedure volume, not refill volume.\u003c\/p\u003e\n\u003cp\u003eThe model also helps keep adoption simple for surgeons and patients, because each unit is tied to one clear clinical event.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician-administered pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhysician-administered pricing means Ocular Therapeutix, Inc. sells through clinical use, not retail shelf sales, so the payer is usually a provider, clinic, or facility. That fits a specialty drug-and-device model because pricing is tied to procedure delivery, reimbursement, and site-of-care economics. It also supports tighter access control than a consumer pharmacy model, which is key for office-based eye care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuy-and-bill reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuy-and-bill pricing for Ocular Therapeutix, Inc. depends on reimbursement in clinics, ASCs, and hospitals, so the list price is only part of the story. U.S. Medicare Part B doctor-administered drugs are often paid at ASP plus 6% before sequestration, which makes payer coverage and coding support key to net realized price. That is standard for specialty ophthalmic products, where faster coverage can widen access and lift realized sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePremium specialty value\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOcular Therapeutix, Inc. can justify premium specialty pricing because DEXTENZA and other sustained-release options reduce repeat dosing and fit into the point of care workflow. That value is tied to fewer drops, less treatment burden, and easier post-procedure care, not just the drug itself. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePremium pricing reflects workflow savings\u003c\/li\u003e\n\u003cli\u003eSustained release lowers dosing burden\u003c\/li\u003e\n\u003cli\u003ePoint-of-care use supports differentiation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNet price management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOcular Therapeutix, Inc. does not keep the list price as realized revenue; rebates, discounts, and payer mix trim it through gross-to-net adjustments, which are common in specialty biopharma and can cut net sales by 20% to 40%. So access matters as much as price: better formulary coverage and fewer patient copays lift the actual net price more than a sticker-price change.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNet price depends on payer mix\u003c\/li\u003e\n\u003cli\u003eRebates lower realized revenue\u003c\/li\u003e\n\u003cli\u003eAccess can beat list price\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcedure-Linked Pricing Drives DEXTENZA Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOcular Therapeutix, Inc. uses procedure-linked pricing: DEXTENZA is a 0.4 mg single-use insert, and revenue depends on the number of eye procedures, not refills. Because it is physician-administered, realized price hinges on coverage, coding, and site-of-care reimbursement. Gross-to-net cuts can still trim specialty net sales by 20% to 40%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePrice driver\u003c\/th\u003e\n\u003cth\u003eKey fact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnit format\u003c\/td\u003e\n\u003ctd\u003e0.4 mg, one use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayment model\u003c\/td\u003e\n\u003ctd\u003eBuy-and-bill\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedicare benchmark\u003c\/td\u003e\n\u003ctd\u003eASP plus 6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet price drag\u003c\/td\u003e\n\u003ctd\u003e20% to 40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234755879177,"sku":"ocul-marketing-mix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ocul-marketing-mix.webp?v=1785727245","url":"https:\/\/dcfanalyst.com\/products\/ocul-marketing-mix","provider":"DCF Analyst","version":"1.0","type":"link"}